Press Releases Year None20232022202120202019 Nov 15, 2023 Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor Nov 09, 2023 Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results Nov 07, 2023 Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast Nov 06, 2023 Repare Therapeutics to Participate in Two Upcoming Investor Conferences Oct 13, 2023 Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib Oct 03, 2023 Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Sep 19, 2023 Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Sep 06, 2023 Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference Aug 09, 2023 Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results Jun 08, 2023 Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 21